Related references
Note: Only part of the references are listed.1-tert-Butyl-3-[6-(3,5-dimethoxy-phenyl)-2-(4-diethylamino-butylamino)- pyrido[2,3-d]pyrimidin-7-yl]-urea (PD173074), a Selective Tyrosine Kinase Inhibitor of Fibroblast Growth Factor Receptor-3 (FGFR3), Inhibits Cell Proliferation of Bladder Cancer Carrying the FGFR3 Gene Mutation along with Up-Regulation of p27/Kip1 and G1/G0 Arrest
Makito Miyake et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2010)
Fibroblast Growth Factor Receptor 1 Promotes Proliferation and Survival via Activation of the Mitogen-Activated Protein Kinase Pathway in Bladder Cancer
Darren C. Tomlinson et al.
CANCER RESEARCH (2009)
Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice
Jing Qing et al.
JOURNAL OF CLINICAL INVESTIGATION (2009)
Mutant fibroblast growth factor receptor 3 induces intracellular signaling and cellular transformation in a cell type- and mutation-specific manner
E. di Martino et al.
ONCOGENE (2009)
FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer
D. C. Tomlinson et al.
JOURNAL OF PATHOLOGY (2007)
Knockdown by shRNA identifes S249C mutant FGFR3 as a potential therapeutic target in bladder cancer
D. C. Tomlinson et al.
ONCOGENE (2007)
Expression of hTERT immortalises normal human urothelial cells without inactivation of the p16/Rb pathway
E. J. Chapman et al.
ONCOGENE (2006)
CHIR-258 is efficacious in a newly developed fibroblast growth factor receptor 3-expressing orthotopic multiple myeloma model in mice
Xiahua Xin et al.
CLINICAL CANCER RESEARCH (2006)
The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells
Suzanne Trudel et al.
BLOOD (2006)
Oncogenic properties of the mutated forms of fibroblast growth factor receptor 3b
I Bernard-Pierrot et al.
CARCINOGENESIS (2006)
Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese?
MA Knowles
CARCINOGENESIS (2006)
FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies
J Chen et al.
ONCOGENE (2005)
Alternative splicing of fibroblast growth factor receptor 3 produces a secreted isoform that inhibits fibroblast growth factor-induced proliferation and is repressed in urothelial carcinoma cell lines
DC Tomlinson et al.
CANCER RESEARCH (2005)
Targeting the extracellular domain of fibroblast growth factor receptor 3 with human single-chain FvAntibodies inhibits bladder carcinoma cell line proliferation
JM Martínez-Torrecuadrada et al.
CLINICAL CANCER RESEARCH (2005)
FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma
AH Jebar et al.
ONCOGENE (2005)
CHIR-258: A potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemia
DEL de Menezes et al.
CLINICAL CANCER RESEARCH (2005)
In vivo target modulation and biological activity of CHIR-258, a multitargeted growth factor receptor kinase inhibitor, in colon cancer models
SH Lee et al.
CLINICAL CANCER RESEARCH (2005)
CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma
S Trudel et al.
BLOOD (2005)
Global cancer statistics, 2002
DM Parkin et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2005)
Urothelial tumorigenesis: A tale of divergent pathways
XR Wu
NATURE REVIEWS CANCER (2005)
The economic consequences of prostate and bladder cancer in the UK
VK Sangar et al.
BJU INTERNATIONAL (2005)
Targeting FGFR3 in multiple myeloma: inhibition of t(4;14)-positive cells by SU5402 and PD173074
EK Grand et al.
LEUKEMIA (2004)
Preclinical studies of fibroblast growth factor receptor 3 as a therapeutic target in multiple myeloma
JL Paterson et al.
BRITISH JOURNAL OF HAEMATOLOGY (2004)
Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma
S Trudel et al.
BLOOD (2004)
A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcript
M Santra et al.
BLOOD (2003)
In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression
JJ Keats et al.
BLOOD (2003)
Analysis of FGFR3 gene mutations in multiple myeloma patients with t(4;14)
D Intini et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
Frequency of fibroblast growth factor receptor 3 mutations in sporadic tumours
K Sibley et al.
ONCOGENE (2001)
Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors
C Billerey et al.
AMERICAN JOURNAL OF PATHOLOGY (2001)
Loss of heterozygosity at 4p16.3 and mutation of FGFR3 in transitional cell carcinoma
K Sibley et al.
ONCOGENE (2001)
Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma
M Chesi et al.
BLOOD (2001)
Share Paper
